Incidence of Dementia With Lewy Bodies and Parkinson Disease Dementia

Rodolfo Savica, MD, MSc; Brandon R. Grossardt, MS; James H. Bower, MD, MSc; Bradley F. Boeve, MD; J. Eric Ahlskog, PhD, MD; Walter A. Rocca, MD, MPH

**IMPORTANCE** Epidemiologic data on dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) remain limited in the United States and worldwide. These data are essential to guide research and clinical or public health interventions.

**OBJECTIVE** To investigate the incidence of DLB among residents of Olmsted County, Minnesota, and compare it with the incidence of PDD.

**DESIGN** The medical records linkage system of the Rochester Epidemiology Project was used to identify all persons who developed parkinsonism and, in particular, DLB or PDD from 1991 through 2005 (15 years). A movement disorders specialist reviewed the complete medical records of each suspected patient to confirm the diagnosis.

**SETTING** Olmsted County, Minnesota, from 1991 through 2005 (15 years).

**PARTICIPANTS** All the residents of Olmsted County, Minnesota, who gave authorization for medical record research.

**MAIN OUTCOMES AND MEASURES** Incidence of DLB and PDD.

**RESULTS** Among 542 incident cases of parkinsonism, 64 had DLB and 46 had PDD. The incidence rate of DLB was 3.5 per 100,000 person-years overall, and it increased steeply with age. The incidence of PDD was 2.5 overall and also increased steeply with age. The incidence rate of DLB and PDD combined was 5.9. Patients with DLB were younger at onset of symptoms than patients with PDD and had more hallucinations and cognitive fluctuations. Men had a higher incidence of DLB than women across the age spectrum. The pathology was consistent with the clinical diagnosis in 24 of 31 patients (77.4%) who underwent autopsy.

**CONCLUSIONS AND RELEVANCE** The overall incidence rate of DLB is lower than the rate of Parkinson disease. The incidence of DLB increases steeply with age and is markedly higher in men. This men to women difference may suggest different etiologic mechanisms. Our findings may guide health care planning and prompt new studies.
Dementia with Lewy bodies (DLB) is a neurodegenerative disorder characterized by parkinsonism and cognitive impairment but may also manifest with dysautonomia, sleep disorders, hallucinations, and cognitive fluctuations. Although first described several decades ago, DLB is still considered a diagnostic challenge because of the clinical and pathological overlap with other neurodegenerative diseases such as Alzheimer disease, Parkinson disease, and frontotemporal lobar degeneration.

The temporal sequence distinguishes DLB from another related condition, Parkinson disease dementia (PDD). The term DLB is used when dementia develops before, or within 1 year after, parkinsonism onset. The term PDD is used when dementia appears more than 1 year after the onset of otherwise typical Parkinson disease. However, PDD and DLB may be manifestations of the same neurodegenerative disorder, possibly related to the abnormal accumulation of α-synuclein.

Limited information is available about the incidence of DLB or PDD in the general population and their distribution by age and sex. To better characterize these 2 disorders, we investigated the incidence of DLB and PDD in a well-defined population over a 15-year period. In addition, we compared the clinical characteristics in patients with DLB vs patients with PDD. For some of the subjects, we were able to validate our clinical diagnosis as compared with autopsy results.

Methods

Case Ascertainment

We studied the geographically defined population of Olmsted County, Minnesota, from January 1, 1991, through December 31, 2005 (15 years). Extensive details about the Olmsted County population were reported elsewhere. In brief, the total population of Olmsted County was 110,780 in 1991 and grew to 138,098 in 2005. The population 65 years and older was 10,603 in 1991 and grew to 14,911 in 2005. The percentage of women was 52.3% in 1991 and 52.4% in 2005.

We ascertained cases of parkinsonism through the medical records linkage system of the Rochester Epidemiology Project. This system provides the infrastructure for indexing and linking essentially all medical information of the county population. All medical diagnoses, surgical interventions, and other procedures are entered into computerized indexes using the Hospital Admission of the International Classification of Diseases, Eighth Revision or the International Classification of Diseases, Ninth Revision.

We ascertained cases of parkinsonism using a computerized screening phase and a clinical confirmation phase, as described in detail elsewhere. In phase 1, we searched the electronic indexes of the records linkage system for 38 diagnostic codes related to parkinsonism. This set of codes was previously validated. In phase 2, a movement disorders specialist (R.S.) defined the type of parkinsonism using specified diagnostic criteria and determined the approximate date of onset of parkinsonism. Onset of parkinsonism was defined as the approximate date in which 1 of the 4 cardinal signs of parkinsonism was first noted by the patient, a family member, or a care provider (as documented in the medical record). To be included in our study, patients were required to reside in Olmsted County at the time of onset of symptoms, and we excluded subjects who denied authorization to use their medical records for research.

Diagnostic Criteria

Our diagnostic criteria included 2 steps: the definition of parkinsonism as a syndrome and the definition of the different types of parkinsonism within the syndrome. Parkinsonism was defined as the presence of at least 2 of 4 cardinal signs: rest tremor, bradykinesia, rigidity, and impaired postural reflexes. Among subjects with parkinsonism, we defined DLB according to the criteria of the 2005 Consensus Conference as presence of parkinsonism and dementia; dementia was defined as a progressive cognitive decline. As stated in the consensus criteria, DLB may be diagnosed when dementia occurs within the first year of the onset of parkinsonism. By contrast, PDD was diagnosed in those patients initially meeting the diagnostic criteria for Parkinson disease who developed dementia more than 1 year after parkinsonism onset. In addition, we abstracted from the medical records information on clinical manifestations such as the presence of hallucinations, cognitive fluctuations, myoclonus, and response to L-Dopa therapy.

Reliability and Validity of Diagnosis

To study the reliability of our case-finding procedure, the records of 40 subjects reviewed by the primary movement disorders specialist (R.S.) were independently reviewed by a second specialist (B.F.B.) who was kept unaware of the initial diagnosis. The 40 subjects were selected randomly among those classified by the primary neurologist as having DLB (10 persons), PDD (10 persons), other types of parkinsonism (10 persons), and parkinsonism excluded after screening positive (10 persons). Agreement on presence of parkinsonism of any kind (including DLB and PDD) was 96.7% (29 of 30). The 1 disagreement involved a person classified as having DLB by the first specialist but excluded by the second specialist. Agreement on exclusion of parkinsonism of any kind in subjects who screened positive was 80.0% (8 of 10). Of the 29 subjects classified as having parkinsonism by both neurologists, the agreement for DLB or PDD vs other types of parkinsonism was 93.1% (27 of 29). Overall, 17 of the 20 subjects classified as having DLB or PDD by the first neurologist were also classified as having DLB or PDD by the second neurologist (85.0% agreement). Finally, for the 17 patients found to be affected by DLB or PDD by both neurologists, the agreement on the year of onset of symptoms was within 1 year in 14 subjects (82.4%) and within 5 years for the remaining 3 subjects (intraclass correlation coefficient = 0.82; 95% CI, 0.66-0.92). To validate the clinical diagnosis, we reviewed the autopsy reports for all the patients who died during the study and for whom an autopsy was available. Detailed results of the validation study are reported in the Results section.

Data Analysis

All individuals who met criteria for DLB or PDD, with symptom onset between January 1, 1991, and December 31, 2005, and who were residents of Olmsted County at the time of onset of symptoms were included as incident cases. We calcu-
### Results

#### Incidence of DLB and PDD

We identified 5505 individuals with at least 1 screening diagnostic code related to parkinsonism during the study years. First, we excluded 400 individuals because they were not residents of Olmsted County at the time of onset of symptoms and 136 subjects because they did not give permission to use their medical records for research. Of the 4969 remaining subjects, 3877 were found to be not affected by parkinsonism; 12 subjects lacked sufficient clinical documentation to determine their parkinsonism status; 374 subjects had onset of parkinsonism before January 1, 1991; and 164 subjects had onset after December 31, 2005. In summary, we identified 542 incident cases of parkinsonism with onset between January 1, 1991, and December 31, 2005, of whom 64 cases had DLB and 46 cases had PDD.\(^{13}\)

Table 1 shows the age- and sex-specific incidence rates (new cases per 100,000 person-years) of DLB, PDD, and DLB and PDD combined. The incidence of DLB was 3.5 per 100,000 person-years overall and was higher in men than in women (4.8 vs 2.2). The incidence of PDD increased with age ranging from 10.3 in persons aged 60 to 69 years, peaking at 44.5 in persons aged 70 to 79 years, and remaining high at 30.1 in persons aged 80 to 99 years. The incidence rate in men was markedly higher than in women after age 60 years (Figure, A).

The incidence of PDD was 2.5 per 100,000 person-years overall and was similar in men and women (2.3 vs 2.7). The overall incidence of PDD increased consistently with age ranging from 0.6 in persons aged 50 to 59 years to 47.0 in persons aged 80 to 99 years. Even though the overall incidence was similar in men and women, the incidence was markedly higher in men than in women in the oldest age group (68.1 in men vs 37.9 in women aged 80-99 years) (Figure, B).

The combined incidence of DLB and PDD was 5.9 overall and was higher in men than in women (7.1 vs 4.9). The incidence rate increased exponentially with increasing age overall and in men and women separately. Men had consistently higher incidence rates than women across the age spectrum (Figure, C).

#### Clinical Characteristics of DLB and PDD

Table 2 summarizes the clinical characteristics of patients diagnosed with DLB and PDD overall and for men and women separately. There were no statistically significant differences between men and women with DLB or PDD for any of the clinical characteristics except for age at diagnosis, which was significantly higher in men than in women (65.9 years vs 63.7 years; p = .007).

### Table 1. Age- and Sex-Specific Incidence Rates of DLB and PDD (Per 100,000 Person-Years) in Olmsted County, Minnesota, from 1991 to 2005\(^{a}\)

<table>
<thead>
<tr>
<th>Type of Parkinsonism</th>
<th>Age Group, y(^{b})</th>
<th>50-59 No. (Rate)</th>
<th>60-69 No. (Rate)</th>
<th>70-79 No. (Rate)</th>
<th>80-99 No. (Rate)</th>
<th>All Ages, 0-99 y(^{c}) No. (Rate)</th>
<th>All Ages, ≥65 y No. (Rate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DLB, men and women</td>
<td>0 (0.0)</td>
<td>12 (10.3)</td>
<td>36 (44.5)</td>
<td>16 (30.1)</td>
<td>64 (3.5)</td>
<td>59 (31.6)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>0 (0.0)</td>
<td>5 (8.2)</td>
<td>9 (19.5)</td>
<td>7 (18.9)</td>
<td>21 (2.2)</td>
<td>18 (16.2)</td>
<td></td>
</tr>
<tr>
<td>PDD, men and women</td>
<td>1 (0.6)</td>
<td>4 (3.4)</td>
<td>16 (19.8)</td>
<td>25 (47.0)</td>
<td>46 (2.5)</td>
<td>43 (23.0)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>0 (0.0)</td>
<td>3 (4.9)</td>
<td>9 (19.5)</td>
<td>14 (37.9)</td>
<td>26 (2.7)</td>
<td>25 (22.5)</td>
<td></td>
</tr>
<tr>
<td>DLB and PDD combined, men and women</td>
<td>1 (0.6)</td>
<td>16 (13.7)</td>
<td>52 (64.3)</td>
<td>41 (77.2)</td>
<td>110 (5.9)</td>
<td>102 (54.6)</td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>1 (1.2)</td>
<td>1 (1.8)</td>
<td>7 (20.2)</td>
<td>11 (68.1)</td>
<td>20 (2.3)</td>
<td>18 (23.8)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>0 (0.0)</td>
<td>8 (14.5)</td>
<td>34 (98.0)</td>
<td>20 (123.8)</td>
<td>63 (7.1)</td>
<td>59 (78.0)</td>
<td></td>
</tr>
<tr>
<td>All Ages, 0-99 y(^{c})</td>
<td>0 (0.0)</td>
<td>8 (13.1)</td>
<td>18 (39.0)</td>
<td>21 (56.8)</td>
<td>47 (4.9)</td>
<td>43 (38.7)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: DLB, dementia with Lewy bodies; PDD, Parkinson disease dementia.

\(^{a}\) Numbers to the left of the rates indicate the actual number of cases. Incidence rates can be computed by dividing the number of cases by the corresponding denominator and multiplying by 100,000. Denominators in person-years for men and women combined were as follows: 0 to 29 years = 843 999; 30 to 49 years = 577 644; 50 to 59 years = 180 689; 60 to 69 years = 116 489; 70 to 79 years = 80 829; 80 to 99 years = 47 142; all ages = 942 37; 60 to 69 years = 86 452; 60 to 69 years = 55 288; 70 to 79 years = 34 695; 80 to 99 years = 16 155; all ages = 888 303; and 65 years and older = 75 652. Denominators for women were as follows: 0 to 29 years = 425 673; 30 to 49 years = 300 227; 50 to 59 years = 94 237; 60 to 69 years = 61 201; 70 to 79 years = 46 134; 80 to 99 years = 36 987; all ages = 964 459; and 65 years and older = 111 001.

\(^{b}\) We did not observe any incident case of DLB or PDD with onset before age 50 years. Therefore, all the numerators for rates in the 0 to 29 years and 30 to 49 years age groups were zero (data not shown).

\(^{c}\) Overall incidence rate for all ages (0-99 years), including the age groups 0 to 29 years and 30 to 49 years.
cal characteristics investigated. By contrast, patients with DLB were younger at onset of symptoms than patients with PDD (median, 76.3 vs 81.4 years) and had a higher frequency of hallucinations (62.5% vs 20.0%) and cognitive fluctuations (25.0% vs 8.9%). Although not reaching statistical significance, patients with DLB also had higher frequency of myoclonus (12.5% vs 4.4%) and were treated less frequently with L-Dopa than patients with PDD (60.9% vs 76.1%).

**Neuropathological Validation of Clinical Diagnosis**

Among the 542 incident cases of parkinsonism of any type, 343 (63.3%) had died at the time of the study and 65 had undergone brain autopsy (19.0% of deceased patients). Among these 65 patients, 31 were classified using our clinical criteria as having DLB or PDD, and 24 of them had Lewy body pathology (77.4% agreement). The agreement of the clinical diagnosis with pathology was 94.1% for DLB (16 patients of 17); the single discrepant case had Alzheimer disease pathology without Lewy bodies or tau inclusions. However, the agreement was only 57.1% for PDD (8 patients of 14). All of the discrepant cases without Lewy bodies had mild to moderate brain atrophy, 4 had mild depigmentation of substantia nigra, 3 had Alzheimer disease pathology, and 1 had tau inclusions.

**Discussion**

There is a paucity of published incidence data relating to DLB despite the fact that DLB is presumed to be the second leading cause of neurodegenerative dementia after Alzheimer disease. The overall incidence rate of DLB in our population-based study was 3.5 cases per 100 000 person-years. To put this into context, Parkinson disease incidence was 4-fold higher, with an incidence rate of 14.2 cases per 100 000 person-years. In fact, the overall incidence of Parkinson disease in our county was 2.4 times higher than the incidence of DLB and PDD combined (14.2 vs 5.9). The lower incidence of DLB than Parkinson disease in our study may partly reflect ascertainment bias. First, some patients may not have had sufficiently distinctive features to allow the diagnosis of DLB and they remained diagnosed as having dementia. Second, our criteria required the presence of parkinsonism to qualify as DLB, and we may have missed those patients with Lewy body pathology in whom parkinsonism remained minimal. Unfortunately, the percentage of subjects found to have Lewy body pathology at autopsy despite having minimal or unrecognized symptoms of parkinsonism varied in the literature but may be sizeable. Therefore, our DLB incidence rates should be regarded as minimum estimates. On the other hand, our access to longitudinal medical records covering the entire duration of medical care should have allowed parkinsonism to surface in all but a small subset of patients with dementia.

There was a striking predominance of DLB incidence in men across all ages, as illustrated in the Figure. During the peak incidence decade (ages 70–79 years), there was approximately a 4-fold incidence rate difference between men and women (77.8 vs 19.5). This exceeds the men to women differences observed for the Parkinson disease incidence rate in the same age group (81.6 vs 69.4). These sex differences may provide important etiologic clues for Parkinson disease and DLB. The different risk in men and women suggests several lines of further research focusing on sex-related factors such as genetic (chromosomes X and Y), endocrinological, and environmental differences or on gender-related factors such as social and cultural differences.
The incidence of PDD was substantially lower than that of DLB (overall incidence rate of 2.5 vs 3.5 cases per 100 000 person-years). However, our PDD incidence findings likely underestimated the true occurrence of this condition. A defining feature of PDD is the development of dementia among patients previously diagnosed with Parkinson disease. In clinical practice, mild dementia may be overshadowed by Parkinson disease problems requiring medication adjustments such as fluctuating motor symptoms, dyskinesias, sleep problems, or dysautonomia. Therefore, only patients with moderate or severe dementia were likely identified.

We included PDD in this study because of the overlap with DLB, both clinically and pathologically. The distinction between DLB and PDD is somewhat arbitrary, although necessary for clinical research, and is based on the time lag between onset of motor symptoms and onset of dementia. Dementia with Lewy bodies and PDD share the same neuropathology, and it is often impossible to differentiate DLB from PDD at autopsy. However, there is a frequent coexistence of Alzheimer disease pathology with DLB, which tends to be modest in typical PDD. Among the patients who underwent autopsy, we had robust neuropathological confirmation of the clinical diagnosis of DLB (94.1%); however, this was not the case for PDD (57.1%). Among the 14 autopsied PDD cases, 6 did not have Lewy bodies. This contrasts with the Parkinson disease cases from our autopsy series where there was confirmation of Lewy bodies in 85.0% of the brains.

One prior population-based study of DLB incidence was conducted in southwestern France (the PAQUID Study). The investigators reported an overall DLB incidence rate of 112.3 cases per 100 000 person-years in subjects 65 years and older. This estimate was based on a total of 29 incident cases of DLB identified using a 2-phase survey involving screening questions and collection of data from general practitioners and specialists. The incidence of DLB in persons 65 years and older was lower in our study at 31.6 per 100 000 person-years. However, in both studies, the risk increased steeply with age and was higher in men.

Our study has a number of strengths. First, taking advantage of the medical records linkage system between diagnosis and death, last contact with the system, or end of study (time of medical record abstraction).

Abbreviations: DLB, dementia with Lewy bodies; IQR, interquartile range (25th percentile–75th percentile); PDD, Parkinson disease dementia.

* Frequencies were compared using \( \chi^2 \) tests and medians using Wilcoxon rank sum tests.

** Follow-up refers to the number of years the patient was captured in the records linkage system between diagnosis and death, last contact with the system, or end of study (time of medical record abstraction).

---

**Table 2. Clinical Characteristics of Incident Cases of DLB and PDD in Olmsted County, Minnesota, from 1991 to 2005**

<table>
<thead>
<tr>
<th>Clinical Characteristics</th>
<th>Men and Women No. (%)</th>
<th>DLB vs PDD P Value*</th>
<th>Men No. (%)</th>
<th>Women No. (%)</th>
<th>Men vs Women P Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>DLB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at onset, y, median (IQR)</td>
<td>76.3 (71.4–80.2)</td>
<td>.002</td>
<td>75.2 (71.2–79.6)</td>
<td>78.1 (70.8–81.9)</td>
<td>.52</td>
</tr>
<tr>
<td>Follow-up, y, median (IQR)</td>
<td>5.3 (3.7–7.9)</td>
<td>.03</td>
<td>5.2 (3.7–7.9)</td>
<td>5.4 (4.4–8.0)</td>
<td>.88</td>
</tr>
<tr>
<td>Education, y, median (IQR)</td>
<td>13 (12–16)</td>
<td>.23</td>
<td>14 (12–17)</td>
<td>12 (12–14)</td>
<td>.17</td>
</tr>
<tr>
<td>L-Dopa ever treated</td>
<td>39 (60.9)</td>
<td>.09</td>
<td>27 (62.8)</td>
<td>12 (57.1)</td>
<td>.66</td>
</tr>
<tr>
<td>L-Dopa responsive, % of treated</td>
<td>23 (59.0)</td>
<td>.55</td>
<td>16 (59.3)</td>
<td>7 (58.3)</td>
<td>.96</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>40 (62.5)</td>
<td>&lt;.001</td>
<td>25 (58.1)</td>
<td>15 (71.4)</td>
<td>.30</td>
</tr>
<tr>
<td>Cognitive fluctuations</td>
<td>16 (25.0)</td>
<td>.03</td>
<td>10 (23.3)</td>
<td>6 (28.6)</td>
<td>.64</td>
</tr>
<tr>
<td>Myoclonus</td>
<td>8 (12.5)</td>
<td>.15</td>
<td>7 (16.3)</td>
<td>1 (4.8)</td>
<td>.19</td>
</tr>
<tr>
<td>Total</td>
<td>64 (100.0)</td>
<td>...</td>
<td>43 (100.0)</td>
<td>21 (100.0)</td>
<td>...</td>
</tr>
<tr>
<td>PDD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at onset, y, median (IQR)</td>
<td>81.4 (76.4–87.4)</td>
<td>...</td>
<td>81.2 (76.2–86.3)</td>
<td>81.9 (76.9–87.7)</td>
<td>.60</td>
</tr>
<tr>
<td>Follow-up, y, median (IQR)</td>
<td>4.2 (1.8–6.4)</td>
<td>...</td>
<td>4.8 (2.2–6.6)</td>
<td>3.9 (1.3–6.8)</td>
<td>.36</td>
</tr>
<tr>
<td>Education, y, median (IQR)</td>
<td>12 (12–16)</td>
<td>...</td>
<td>12 (12–16)</td>
<td>12 (9–15)</td>
<td>.17</td>
</tr>
<tr>
<td>L-Dopa ever treated</td>
<td>35 (76.1)</td>
<td>...</td>
<td>14 (70.0)</td>
<td>21 (80.8)</td>
<td>.40</td>
</tr>
<tr>
<td>L-Dopa responsive, % of treated</td>
<td>23 (65.7)</td>
<td>...</td>
<td>8 (57.1)</td>
<td>15 (71.4)</td>
<td>.38</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>9 (20.0)</td>
<td>...</td>
<td>4 (21.1)</td>
<td>5 (19.2)</td>
<td>.88</td>
</tr>
<tr>
<td>Cognitive fluctuations</td>
<td>4 (8.9)</td>
<td>...</td>
<td>1 (5.3)</td>
<td>3 (11.5)</td>
<td>.47</td>
</tr>
<tr>
<td>Myoclonus</td>
<td>2 (4.4)</td>
<td>...</td>
<td>1 (5.3)</td>
<td>1 (3.8)</td>
<td>.82</td>
</tr>
<tr>
<td>Total</td>
<td>46 (100.0)</td>
<td>...</td>
<td>20 (100.0)</td>
<td>26 (100.0)</td>
<td>...</td>
</tr>
</tbody>
</table>

Abbreviations: DLB, dementia with Lewy bodies; IQR, interquartile range (25th percentile–75th percentile); PDD, Parkinson disease dementia.

* Frequencies were compared using \( \chi^2 \) tests and medians using Wilcoxon rank sum tests.

** Follow-up refers to the number of years the patient was captured in the records linkage system between diagnosis and death, last contact with the system, or end of study (time of medical record abstraction).

* Of the 46 persons with PDD, only 45 had information available regarding hallucinations, cognitive fluctuations, and myoclonus.
as DLB and PDD. Fourth, 63.3% of cases were followed up from the onset of the disease to the time of death, and 94.3% were followed up through death or for at least 5 years after onset. Fifth, all of the cases were adjudicated by a movement disorders specialist at the time of records abstraction to reduce differences in the diagnostic criteria over time or across the different care providers. In addition, we compared the initial diagnosis given by the primary movement disorders specialist (R.S.) with the diagnosis given independently by another specialist (B.F.B.) in a subsample of subjects and found good agreement. Finally, the agreement of clinical diagnosis with autopsy findings was good, particularly for DLB, suggesting that our clinical classification of patients was valid.

Our study also has a number of limitations. First, it is possible that some patients with mild symptoms went unrecognized and, hence, undiagnosed. However, our data collection spanned across 20 years, and we collected data for an additional 5 years after the study period (2006-2010). This allowed us to appropriately retro date the time of onset of symptoms when needed. Second, some of the clinical features (eg, cognitive fluctuations) were not systematically recorded in the medical records, and thus, certain clinical features may have gone unrecognized. Third, because cognitive status was not systematically studied in all patients with parkinsonism, some patients with cognitive complaints may have been overlooked. Indeed, in clinical practice, if patients have already been diagnosed with Parkinson disease, they may not receive an additional diagnosis of dementia. On the other hand, when dementia is the first symptom or the major manifestation, such as in DLB, cognitive symptoms are specifically evaluated and diagnosed; however, an additional diagnosis of parkinsonism may not be given, especially in older subjects with severe nonneurological comorbidities (Figure, A). Finally, Olmsted County is a primarily white community of persons of European descent, and our findings may not be generalizable to other populations with different ethnic, social, and economic characteristics; however, the population is similar to a large portion of the US population.8

In conclusion, our study provides unique population-based data on the incidence of DLB and PDD in Olmsted County. Similar to Parkinson disease, the risk of DLB increases with older age and is more frequent in men. Interestingly, the men vs women incidence rate ratio is greater for DLB than for Parkinson disease and may suggest different etiologic mechanisms for DLB in men vs women.

REFERENCES


